Prozac (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 17 | Multiple system atrophy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-004922-26-FR (EUCTR) | 12/02/2008 | 31/01/2008 | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | atrophie multisystématisée MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: PROZAC | CHU Toulouse | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France |